Longeveron Soars 37% As Phase 1 Study for Alzheimer Treatment Shows Success
(Longeveron) Shares of Longeveron Inc. rose more than 37% on Thursday after its phase 1 study trials of Lomecel-B on patients with mild forms of Alzheimer disease showed success. Longeveron…